Introduction
============

Kv1 channels are *shaker*-related, voltage-gated potassium channels ([@ref-9]). It has been proposed that compounds that block the Kv1.3 channel might be used in the treatment of type 2 diabetes and obesity ([@ref-3]). Thus, a variant of the human Kv1.3 gene is associated with low insulin sensitivity and impaired glucose tolerance ([@ref-18]), whereas Kv1.3^−/−^ mice were protected from diet-induced insulin resistance ([@ref-22]) and obesity ([@ref-23]). Some studies on inhibitors of Kv1.3 have demonstrated their ability to improve insulin sensitivity in mice ([@ref-23]; [@ref-20]), but another has failed to show any benefit ([@ref-17]).

In those studies in which improved insulin sensitivity has been shown, the tissues where the inhibitors have their primary action are uncertain. Kv1.3 channels in liver, postganglionic sympathetic neurons and brown adipose tissue are suggested targets ([@ref-20]). It is unclear whether white adipose tissue or skeletal muscle could be the primary site of action because there is disagreement as to whether Kv1.3 is expressed, particularly at the protein level, in these tissues ([@ref-7]; [@ref-13]; [@ref-17]; [@ref-20]). Nevertheless, the Kv1.3 inhibitor margatoxin decreased TNF*α* secretion by white adipose tissue from genetically obese (*ob/ob*) mice ([@ref-23]), and administration of the highly selective Kv1.3 inhibitor ShK-186 for 45 days to mice fed on an obesity-inducing diet reduced TNF*α* mRNA in visceral adipose tissue ([@ref-20]). The target for the latter effect might be Kv1.3 channels in inflammatory cells, such as macrophages. Decreased inflammation of adipose tissue, including decreased secretion of TNF*α*, would be expected to improve insulin sensitivity ([@ref-2]).

As part of an investigation into the potential of Kv1.3 inhibitors for the treatment of type 2 diabetes, we have studied the effect of 5-(4-phenoxybutoxy)psoralen (PAP-1) on glucose uptake in white adipocytes and soleus muscle, and TNF*α* secretion by white adipocytes from wild-type and *ob/ob* mice. PAP-1 is a selective inhibitor of Kv1.3, being at least 23-fold selective as an inhibitor of Kv1.3 over other Kv1-family channels and 500-fold selective over Kv2.1, Kv3.1, Kv3.2 and Kv4.2 channels ([@ref-16]). We report that a concentration of PAP-1 that is not selective for Kv1.3 stimulated glucose uptake and reduced TNF*α* secretion, but a lower concentration was ineffective, in agreement with the results of others ([@ref-1]; [@ref-17]). This raised the question of the target for the non-selective concentration of PAP-1 and led us to investigate the expression of Kv1.1, Kv1.2, Kv1.3 and Kv1.5 in mouse skeletal muscle and white adipose tissue. Kv1.5 is identified as a candidate mediator of the effects of PAP-1 on glucose uptake.

Materials and Methods
=====================

Materials
---------

All materials, including PAP-1 (\>98% purity), were obtained from Sigma-Aldrich, Poole, UK, unless otherwise stated.

Animals
-------

Housing and procedures were conducted in accordance with the UK Government Animal (Scientific procedures) Act 1986 and approved by the University of Buckingham Ethical review Board. C57Bl/6 and *ob/ob* mice (Harlan, Bicester, UK), aged 5--6 weeks, were fed standard laboratory chow *ad libitum* and euthanized 3--4 h after the onset of day light cycle, by a UK Government Animal Scientific Act 1986 schedule 1 method.

RT-PCR
------

Tissues isolated from wild-type and *ob/ob* female C57Bl/6 mice were homogenized in Tri-reagent using a ribolyser and total RNA prepared using Qiagen™ minicolumns according to the manufacturer's instructions. One µg total RNA was reverse-transcribed using avian reverse transcriptase and random priming in a 50 µl reaction. Two µl cDNA was subsequently used per 50 µl PCR reaction as standard. GAPDH was chosen as the housekeeping genes because it showed consistent C~*T*~ values in adipose tissue, adipocytes and soleus muscle. Gene expression assays were obtained from Applied Biosystems Assay-on-Demand predesigned and optimized assays.

Subsequently, tissues were isolated from wild-type female C57Bl/6 mice. Total RNA was extracted and RT PCR performed by Real Time PCR using optimized Assay-on-Demand (Applied Biosystems) primers and probes for Kv1.1, 1.2, 1.3 and 1.5, relative to an endogenous GAPDH control ([@ref-21]). Expression of each potassium channel was calculated relative to expression of GAPDH in each sample and then the expression levels of Kv1.2 and Kv1.5 were expressed relative to Kv1.3 in the same tissue ([@ref-21]). Multiple Kv channels were not run in the same PCR reaction in order to prevent competition between the cDNA templates for the amplification reactants and to optimize reaction efficiency.

2-Deoxyglucose uptake by soleus muscle
--------------------------------------

Uptake of 2-deoxyglucose by the soleus muscle was measured by a method that we have described previously ([@ref-14]). Soleus muscles were dissected from both hind legs of wild-type and *ob/ob* C57Bl/6 male mice. Distal and proximal tendons were tied under resting tension to stainless steel clips and pre-incubated for 60 min in Krebs-Henseleit bicarbonate buffer that contained 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 5.5 mM glucose and 0.14% (w/v) fatty acid-free bovine serum albumin (BSA) at pH 7.4 and 37 °C. The buffer had been gassed previously with 95% O~2~: 5% CO~2~. They were then incubated for 45 min in fresh medium that also contained 2-deoxy\[1-^14^C\] glucose (56 mCi mmol^-1^; 0.1 µCi ml^-1^) and glucose (5.5 mM), with or without insulin (10 nM for wild-type mice and 100 nM for *ob/ob* mice) and PAP-1 (3 µM) or a combination of insulin and PAP-1.

At the end of the incubation, the muscles were digested with 1 M NaOH and the digest was neutralised with 1 M HCl. One portion of the mixture was treated with 2.5 volumes of 6% (w/v) perchloric acid to precipitate out proteins, leaving supernatant that contained both 2-deoxyglucose and 2-deoxyglucose-6-phosphate. Another portion was treated with 2.5 volumes of 2.68% (w/v) Ba(OH)~2~ and 2.51% (w/v) ZnSO~4~ to precipitate out 2-deoxyglucose-6-phosphate. Radioactivity incorporated into 2-deoxyglucose-6-phosphate was obtained from the difference between that in the two supernatants. 2-Deoxyglucose uptake was calculated by dividing radioactivity in 2-deoxyglucose-6-phosphate by the specific activity of 2-deoxyglucose.

Glucose uptake by adipocytes
----------------------------

Adipocytes were prepared from the parametrial fat pads of wild-type and *ob/ob* female mice by a method that we have described previously ([@ref-25]). Tissue was minced and digested with collagenase type II in Krebs-Ringer HEPES buffer containing 10 mM HEPES, 1% bovine serum albumin (fraction V), 2.5 mM CaCl~2~, 5.5 mM glucose and 200 nM adenosine at pH 7.4 and 37 °C. It was filtered through 250--300 µm nylon mesh. The infranatant was removed and the floating layer of adipocytes was washed four times with a fresh buffer. Adipocytes were concentrated to 40% of final volume of Krebs-Ringer HEPES buffer containing 5% BSA and 0.3 mM glucose and pre-incubated for 45 min under 95% O~2~: 5% CO~2~ before dispensing them into 300 µl polyethylene tubes for measurement of glucose uptake.

Glucose transport was measured as described previously ([@ref-12]). Adipocytes were incubated in Krebs-Ringer HEPES buffer containing BSA, 0.3 mM glucose and D-\[U-^14^C\] glucose (0.2 µmol/l; 0.2 µCi/ml), for 1 h at 37 °C in the absence or presence of different concentrations of PAP-1 and insulin. The reaction was stopped by separation of the cells through silicone oil and radioactivity in the cells was measured. Extracellular space was measured in parallel incubations using D-\[U-^14^C\] sucrose. Secretion is expressed per mg protein, determined using a method based on the Lowry assay (Bio-Rad, Hemel Hempstead, UK) or per g cells.

TNF*α* and IL-6 secretion
-------------------------

Adipose tissue from *ob/ob* and wild-type female mice was minced into pieces weighing about 200 mg and added to 0.3 ml Dulbecco's modified Eagle's medium and Ham's F-12 in a 1:1 mixture (both from Invitrogen, Paisley, UK), supplemented with 0.5% (w/v) endotoxin-free BSA . The incubation medium also contained 1 nM T3 and 5 mM glutamine. The plates were incubated with or without PAP-1 (3 µM) for 30 min. TNF*α* and IL-6 in the culture medium was assayed using murine ELISA kits (from Diaclone, Besançon, France for TNF; from Invitrogen for IL-6) , following the manufacturer's instructions. Secretion is expressed per mg protein, determined using the Lowry assay.

Statistical analysis
--------------------

Glucose uptake was calculated assuming that 2-deoxyglucose and glucose are not distinguished by uptake mechanisms. Data were analyzed by one- or two-way ANOVA followed by Fisher's least significant difference test, as described in the figure legends, using GraphPad Prism version 5 (GraphPad software, San Diego CA, USA). Results are expressed as means ± SEM.

Results
=======

Glucose uptake in soleus muscle
-------------------------------

Insulin (10 nM) and PAP-1 (3 µM) stimulated 2-deoxyglucose uptake in soleus muscle from both wild-type and *ob/ob* mice ([Fig. 1](#fig-1){ref-type="fig"}). The combination of insulin and PAP-1 also stimulated uptake compared to baseline in muscle from both wild-type and *ob/ob* mice (*P* \< 0.001), but it did not have a significantly greater effect than either insulin or PAP-1 alone.

![Effect of PAP-1 on glucose uptake in soleus muscles of male (A) wild-type and (B) *ob/ob* C57Bl6 mice.\
Muscles were treated with insulin (wild-type, 10 nM; *ob/ob*, 100 nM) or PAP-1 (3 µM) alone, or the combination of insulin and PAP-1. *n* = 8 mice per group for all columns. Data for each genotype were analyzed by one-way ANOVA followed by Fisher's least significant difference test. ^∗^ *P* \< 0.05; ^∗∗∗^ *P* \< 0.001 for effect of PAP-1 compared to controls (Con). ^†^*P* \< 0.05; ^†††^*P* \< 0.001 for effect of insulin (Ins) compared to controls. ^‡‡‡^*P* \< 0.001 for the effect of the combination of PAP-1 and insulin compared to the absence of both compounds (Con). Note that in both wild-type and *ob/ob* mice, glucose uptake in the presence of the combination of PAP-1 and insulin was not significantly greater than in the absence of one of the compounds.](peerj-02-614-g001){#fig-1}

Glucose uptake in Adipocytes
----------------------------

PAP-1 (3 µM) stimulated glucose in adipocytes from both wild-type and obese mice in the absence of insulin. In the presence of insulin at a range of concentrations, its effect was significant only in adipocytes from *ob/ob* mice ([Fig. 2](#fig-2){ref-type="fig"}). In the absence of PAP-1, insulin stimulated uptake at concentrations of 0.5 nM and higher. The combination of insulin and PAP-1 stimulated uptake compared to baseline, but insulin did not stimulate glucose uptake significantly in the presence of PAP-1. A concentration--response curve conducted using adipocytes from wild-type mice in the absence of insulin showed significant effects of PAP-1 at 1 and 3 µM, but not at lower concentrations ([Fig. 3](#fig-3){ref-type="fig"}).

![Effect of PAP-1 on glucose uptake in adipocytes of female (A) wild-type and (B) *ob/ob* C57Bl6 mice.\
Adipocytes were treated with insulin, PAP-1 (*P*, 3 µM) alone, or a combination of insulin and PAP-1. *n* = 8 mice per group for all columns. Data for each genotype were analyzed by two-way ANOVA (sources of variation: PAP-1 and insulin concentrations), followed by Fisher's least significant difference test, first for the paired columns at the same concentration of insulin, and second to test for an effect of insulin compared to the value obtained in the absence of insulin but in the presence of the same concentration (0 or 3 microM) of PAP-1. ^∗^ *P* \< 0.05; ^∗∗^*P* \< 0.01 for effect of PAP-1 compared to controls at the same concentration of insulin (C). ^†^*P* \< 0.05; ^††^*P* \< 0.01; ^†††^*P* \< 0.001 for effect of insulin compared to no insulin at the same concentration of PAP-1.](peerj-02-614-g002){#fig-2}

![Concentration-response curve for the effect of PAP-1 on glucose uptake in the absence of insulin in adipocytes of female wild-type C57Bl6 mice.\
*n* = 8 mice per group for all columns. Data were analyzed by one-way ANOVA followed by Fisher's least significant difference test against the control value. ^∗^*P* \< 0.05; ^∗∗∗^*P* \< 0.001 for effect of PAP-1 compared to baseline.](peerj-02-614-g003){#fig-3}

TNF*α* and IL-6 secretion
-------------------------

PAP-1 (3 µM) suppressed the secretion of TNF*α* by 50% in adipocytes from both wild-type and *ob/ob* mice ([Fig. 4](#fig-4){ref-type="fig"}). PAP-1 did not affect IL-6 secretion (results not shown). Surprisingly, secretion of TNF*α* from *ob/ob* adipocytes was lower than from wild-type adipocytes. Others have found a higher concentration of TNF*α* in adipocytes from *ob/ob* compared to wild-type adipocytes ([@ref-5]).

![Effect of PAP-1 (3 µM) on TNF*α* secretion by adipocytes from female wild-type and *ob/ob* mice.\
*n* = 6 mice per group for all columns. Data were log~10~-transformed so that variances were not significantly different between groups prior to analysis by two-way ANOVA (sources of variation: genotype and PAP-1 concentration), followed by Fisher's least significant difference test. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01 for effect of PAP-1 compared to control (Con).](peerj-02-614-g004){#fig-4}

Expression of Kv1mRNA
---------------------

Using reverse transcription PCR, Kv1.3 mRNA was detected in liver, gastrocnemius muscle, soleus muscle and parametrial white adipose tissue of female wild-type and *ob/ob* mice, except that expression was not significantly above baseline in gastrocnemius muscle from wild-type mice ([Fig. 5A](#fig-5){ref-type="fig"}). Expression was higher in liver, gastrocnemius muscle and soleus muscle, but not adipose tissue, of *ob/ob* mice compared to wild-type mice. Kv1.5 mRNA was detected in liver, gastrocnemius muscle, soleus muscle and parametrial white adipose tissue of female wild-type and *ob/ob* mice, except that expression could not be detected in livers from wild-type mice ([Fig. 5B](#fig-5){ref-type="fig"}). Expression was higher in liver and soleus muscle of *ob/ob* mice compared to wild-type mice.

![Kv1.3 and Kv1.5 mRNA levels in liver, gastrocnemius, soleus and white adipose tissue of female (A) wild-type and (B) *ob/ob* mice.\
*n* = 3 mice for all columns. Expression of each potassium channel was calculated relative to expression of GAPDH in each sample. Data were log~10~-transformed prior to statistical analysis because the data obtained for [Fig. 6](#fig-6){ref-type="fig"} suggested that widely distributed data did not follow a normal distribution without this transformation. Analysis was by two-way ANOVA (sources of variation: genotype and tissue) for each gene, followed by Fisher's least significant difference test for each pair of wild-type and *ob/ob* values. Unpaired *t*-tests conducted on untransformed data gave the same significant differences. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001 compared to wild-type mice.](peerj-02-614-g005){#fig-5}

After it was found that PAP-1 did not stimulate glucose uptake by adipocytes at concentrations that should be sufficient to activate Kv1.3, Real-Time PCR was used to detect mRNA for Kv1.1, Kv1.2, Kv1.3 and Kv1.5 in each of adipose tissue, adipocytes and soleus muscle. Assuming PCR reaction efficiencies of 1.0 for each gene, Kv1.5 was 30-, 15- and 78-fold more highly expressed than Kv1.3 in adipose tissue, adipocytes and soleus muscle respectively. Kv1.2 mRNA could not be detected in adipocytes and appeared to have lower expression than Kv1.3 in adipose tissue ([Fig. 6](#fig-6){ref-type="fig"}). Kv1.1 could not be detected in adipose tissue, adipocytes or soleus muscle.

![Relative expression of Kv1.2, Kv1.3 and Kv1.5 expression in (A) adipose tissue, (B) adipocytes and (C) soleus muscle of wild-type mice.\
Relative expression is given assuming that PCR reaction efficiencies were 1.0 for each gene. The expression of each Kv channel was expressed relative to GAPDH in the same sample and then relative to Kv1.3. Δ*C~T~* GAPDH--Δ*C~T~* Kv1.3 was 4.43 ± 0.31 for adipose tissue, 6.32 ± 0.34 for adipocytes and 9.8 ± 0.70 for soleus muscle (*n* = 6). Data were log~10~-transformed prior to statistical analysis because variances were clearly higher for Kv1.5, which was far more highly expressed than Kv1.2 or Kv1.3. Thus the Bartlett and *F*-tests showed significant differences in variance for the adipose tissue and adipocyte data respectively when these data were not transformed. Analysis was by two-way ANOVA (sources of variation: gene and tissue), followed by Fisher's least significant difference test for adipose tissue and soleus muscle. Kv1.2 was undetectable in adipocytes, so Kv1.3 and Kv1.5 were compared by unpaired *t*-test. *n* = 4 mice for soleus muscle and 6 mice for adipose tissue and adipocytes. ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001.](peerj-02-614-g006){#fig-6}

Discussion
==========

A variety of evidence suggests that inhibition of Kv1.3 potassium channels might be effective in the treatment of insulin resistance, and thereby of type 2 diabetes ([@ref-3]; [@ref-20]). This includes the finding that margatoxin, which inhibits members of the Kv1 family, including Kv1.3, lowered blood glucose in wild-type but not Kv1.3^−/−^ mice ([@ref-23]). The authors linked this finding to the demonstration that margatoxin inhibited the secretion of TNF*α* and IL-6 by isolated adipocytes in adipose tissue and skeletal muscle after it was administered to wild-type but not Kv1.3^−/−^ mice. The tissues that contain the Kv1.3 channels at which the inhibitors exert their initial effects have not been well-defined, however.

We investigated whether the initial effects of Kv1.3 inhibitors might be on Kv1.3 channels in adipocytes or skeletal muscle using PAP-1. PAP-1 inhibits Kv1.3 with 33-fold selectivity over Kv1.1, 125-fold selectivity over Kv1.2 and 23-fold selectivity over Kv1.5 ([@ref-16]). Inhibition of K channels might be expected to lead to cell depolarization and an increased demand for energy. We found that PAP-1 at the high concentration of 3 µM stimulated glucose uptake in the absence of insulin in isolated soleus muscle and adipocytes from both wild-type and *ob/ob* mice. PAP-1 also stimulated glucose uptake in the presence of a range of concentrations of insulin in adipocytes from *ob/ob* mice. The same concentration of PAP-1 (3 µM) also reduced the secretion of TNF*α* by adipocytes, potentially consistent with the suggestion of others ([@ref-23]) that this is a mechanism by which blockade of Kv1.3 improves insulin sensitivity. However, when we investigated the concentration--response curve for the effect of PAP-1 on glucose uptake, we found that, whilst 1 µM was effective, a concentration of 300 nM, which is still 150-fold higher than its EC~50~ value for blockade of murine Kv1.3 ([@ref-16]), had no effect on glucose uptake.

These experiments were conducted using tissues from female mice, except that soleus muscles from male mice were used for studying glucose uptake. These choices were in line with our previous work, allowing more accurate quality control by comparison with our historic data. Most studies of the effects of Kv1.3 inhibitors on metabolism have been conducted using male mice, but two studies have shown that deletion of the Kv1.3 gene has similar metabolic effects in male and female mice ([@ref-22]; [@ref-19]).

Our results are consistent with a report that PAP-1 failed to lower blood glucose or enhance the glucose lowering effect of insulin when administered as a single dose or over five days to *ob/ob* or *db/db* mice in amounts that gave blood levels that would selectively block Kv1.3. Moreover, 10 nM PAP-1, a concentration fivefold higher than its IC~50~ value for inhibition of Kv1.3 channels, did not alter K^+^ currents in a human skeletal muscle cell line or glucose uptake in mouse 3T3-L1 adipocytes ([@ref-17]). Similarly, margatoxin did not stimulate glucose utilization by rat epididymal or mesenteric adipocytes ([@ref-1]) when used at concentrations (1 or 100 nM) well above its EC~50~ value (30 pM) for inhibition of Kv1.3 ([@ref-6]). [@ref-20] have reported that the highly selective Kv1.3 inhibitor ShK-186 reduces obesity and hyperglycemia in mice fed on an obesogenic diet, but they too rule out an involvement of white adipocyte or skeletal muscle Kv1.3 channels, mainly because ShK-186 did not stimulate glucose uptake by white adipose tissue or skeletal muscle. ShK-186 doubled glucose uptake in brown adipose tissue, a site of high glucose uptake and uncoupled oxidative phosphorylation, making this a more likely explanation for the anti-obesity and anti-hyperglycemic effects of ShK-186, in their view. The same group had previously reported that ShK-186 also failed to stimulate glucose uptake by rat white adipocytes ([@ref-1]).

Although we do not believe that PAP-1 affected glucose uptake by inhibiting Kv1.3, we did detect Kv1.3 mRNA in murine adipose tissue and skeletal muscle (and also liver). Others appear to disagree as to whether Kv1.3 protein is expressed in murine adipose tissue, but this may be because one group used isolated epididymal adipocytes ([@ref-13]) and the other visceral adipose tissue ([@ref-20]). No Kv1.3 protein was detected in murine skeletal muscle ([@ref-20]) or in samples of adipose tissue and skeletal muscle from two normal and two type 2 diabetic human subjects ([@ref-17]). One possible interpretation of these reports and our findings is that the expression of Kv1.3 is very low in adipose tissue and skeletal muscle, and is sometimes undetectable at the protein level, despite being detectable at the mRNA level. We found more Kv1.3 mRNA in tissues from *ob/ob* than wild-type mice, except for white adipose tissue, but given the relative amounts of adipose tissue in the wild-type and obese animals, the total amount of Kv1.3 mRNA in adipose tissue per animal may be higher in the *ob/ob* mice. We also found more Kv1.5 mRNA in liver and soleus muscle of *ob/ob* compared to lean mice. These results would be consistent with expression of either channel contributing to insulin resistance in *ob/ob* mice.

Levels of Kv1.5 mRNA appeared much higher than those of Kv1.3 in both adipocytes and soleus muscle. It is well-established that Kv1.5 is expressed in skeletal muscle ([@ref-11]) but its expression in adipose tissue or adipocytes has not been reported. We cannot exclude the possibility that our results are influenced to some extent by the PCR reaction efficiency differing between genes, but this seems unlikely to alter our conclusion that the expression of Kv1.5 was much higher than that of Kv1.3 or Kv1.2 ([@ref-10]). In any event, irrespective of the precise differences in expression of the Kv genes, our findings raise the possibility that Kv1.5 was the channel that PAP-1 inhibited to stimulate glucose uptake and inhibit TNF*α* secretion. If so, Kv1.5 inhibitors might have potential in the treatment of type 2 diabetes. PAP-1 has been reported to inhibit Kv1.5 with an EC~50~ value of 45 nM ([@ref-16]), but it failed to stimulate glucose uptake in adipocytes when present at a concentration of 300 nM. The 6.7-fold lower EC~50~ value of 45 nM was, however, measured with Kv1.5 from a different species and under very different conditions: it was obtained by applying depolarizing pulses to mouse erythroleukaemia (MEL) cells stably transfected with human Kv1.5 and measuring the reduction in area under the current curve ([@ref-8]). By contrast, no depolarizing stimulus was applied in our work and we used mouse tissue. Whilst the EC~50~ value of 2 nM for PAP-1 at Kv1.3 was also determined by an electrophysiological technique, it did use murine Kv1.3 ([@ref-16]), and it is less likely that the much higher (150-fold) discrepancy between this value and the minimum effective dose of PAP-1 for stimulation of glucose uptake can be explained in terms of the different test systems. PAP-1 is less potent at Kv1.2 (EC~50~ = 250 nM) than Kv1.5 ([@ref-16]), and Kv1.2 mRNA could not be detected in adipocytes using Real Time RCR, ruling it out as a candidate target for PAP-1 in this tissue. We cannot rule out the possibility that Kv1.4, Kv1.6 or Kv1.7 could be the targets of PAP-1 in adipocytes and skeletal muscle, but Kv1.4 is poorly expressed in human adipocytes ([@ref-24]), and 100 nM margatoxin did not stimulate glucose uptake in rat epididymal adipocytes ([@ref-1]), despite having an EC~50~ value for inhibition of Kv1.5 of 5 nM ([@ref-6]).

We therefore conclude that although Kv1.3 mRNA could be detected in murine white adipose tissue, white adipocytes and red skeletal muscle, inhibition of Kv1.3 does not directly affect glucose uptake in white adipocytes or skeletal muscle. Blockade of Kv1.5 channels in white adipocytes or skeletal muscle might, however, stimulate glucose uptake. Studies using novel Kv1.5 inhibitors might be informative, but their selectivities have been given only relative to other cardiac K channels and not to other Kv1 channels ([@ref-4]; [@ref-15]). We do not exclude the possibility that compounds might be useful in the treatment of obesity and insulin resistance, by inhibiting Kv1.3 in other tissues.
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